MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Molina Pinelo, Sonia ^a   Carnero, Amancio ^a   Rivera, Fernando ^b   Estevez Garcia, Purificacion ^a   Bozada, Juan Manuel ^a   Limon, Maria Luisa ^a   Benavent, Marta ^a   Gomez, Javier ^b   Pastor, Maria Dolores ^a   Chaves, Manuel ^a   Suarez, Rocio ^a   Paz Ares, Luis ^a   de la Portilla, Fernando ^a   Carranza Carranza, Andres ^a   Sevilla, Isabel ^c   Vicioso, Luis ^c   Garcia Carbonero, Rocio ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

Advanced colorectal cancer; Chemotherapy response; MicroRNAs; Prediction

Indexed keywords

CYCLIN D1; IRINOTECAN; MESSENGER RNA; MICRORNA; MICRORNA 107; MICRORNA 299-5P; MICRORNA 337-5P; MICRORNA 370; MICRORNA 889; MICRORNA 99A-3P; MICRORNA LET-7; OXALIPLATIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MIRN107 MICRORNA, HUMAN; MIRN99 MICRORNA, HUMAN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CCND1 GENE; DICER1 GENE; DROSHA GENE; DRUG RESPONSE; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; NFKB1 GENE; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; METASTASIS; MIDDLE AGED; MORTALITY; SURVIVAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84907022030     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-656     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90. 10.3322/caac.20107, 21296855.
2. Parkin DM. International variation. Oncogene 2004, 23(38):6329-6340. 10.1038/sj.onc.1207726, 15322508.
3. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009, 27(19):3109-3116. 10.1200/JCO.2008.20.6771, 19451431.
4. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18(16):2938-2947.
5. Cunningham D, Sirohi B, Pluzanska A, Utracka-Hutka B, Zaluski J, Glynne-Jones R, Koralewski P, Bridgewater J, Mainwaring P, Wasan H, Wang JY, Szczylik C, Clingan P, Chan RT, Tabah-Fisch I, Cassidy J. Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Ann Oncol 2009, 20(2):244-250.
6. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355(9209):1041-1047. 10.1016/S0140-6736(00)02034-1, 10744089.
7. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000, 343(13):905-914. 10.1056/NEJM200009283431302, 11006366.
8. Garcia-Carbonero R, Gomez Espana MA, Casado Saenz E, Alonso Orduna V, Cervantes Ruiperez A, Gallego Plazas J, Garcia Alfonso P, Juez Martel I, Gonzalez Flores E, Lomas Garrido M, Isla Casado D. SEOM clinical guidelines for the treatment of advanced colorectal cancer. Clin Transl Oncol 2010, 12(11):729-734. 10.1007/s12094-010-0587-4, 20974564.
9. Aranda E, Abad A, Carrato A, Cervantes A, Garcia-Foncillas J, Garcia Alfonso P, Garcia Carbonero R, Gomez Espana A, Tabernero JM, Diaz-Rubio E. Treatment recommendations for metastatic colorectal cancer. Clin Transl Oncol 2011, 13(3):162-178. 10.1007/s12094-011-0636-7, 21421461.
10. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314(5797):268-274. 10.1126/science.1133427, 16959974.
11. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318(5853):1108-1113. 10.1126/science.1145720, 17932254.
12. Nagel R, le Sage C, Diosdado B, van der Waal M, Oude Vrielink JA, Bolijn A, Meijer GA, Agami R. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res 2008, 68(14):5795-5802. 10.1158/0008-5472.CAN-08-0951, 18632633.
13. Ruzzo A, Graziano F, Vincenzi B, Canestrari E, Perrone G, Galluccio N, Catalano V, Loupakis F, Rabitti C, Santini D, Tonini G, Fiorentini G, Rossi D, Falcone A, Magnani M. High Let-7a MicroRNA levels in KRAS-mutated colorectal carcinomas May rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. Oncologist 2012, 17(6):823-829. 10.1634/theoncologist.2012-0081, 3380881, 22584434.
14. Ragusa M, Majorana A, Statello L, Maugeri M, Salito L, Barbagallo D, Guglielmino MR, Duro LR, Angelica R, Caltabiano R, Biondi A, Di Vita M, Privitera G, Scalia M, Cappellani A, Vasquez E, Lanzafame S, Basile F, Di Pietro C, Purrello M. Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Mol Cancer Ther 2010, 9(12):3396-3409. 10.1158/1535-7163.MCT-10-0137, 20881268.
15. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. RAS is regulated by the let-7 microRNA family. Cell 2005, 120(5):635-647. 10.1016/j.cell.2005.01.014, 15766527.
16. Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, Cai X, Wang K, Wang G, Ba Y, Zhu L, Wang J, Yang R, Zhang Y, Ren Z, Zen K, Zhang J, Zhang CY. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009, 28(10):1385-1392. 10.1038/onc.2008.474, 19137007.
17. Tsang WP, Kwok TT. The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis 2009, 30(6):953-959. 10.1093/carcin/bgp094, 19372139.
18. Guo C, Sah JF, Beard L, Willson JK, Markowitz SD, Guda K. The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer 2008, 47(11):939-946. 10.1002/gcc.20596, 2739997, 18663744.
19. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008, 9(6):582-589. 10.1038/embor.2008.74, 2396950, 18483486.
20. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, Gimotty PA, Katsaros D, Coukos G, Zhang L, Pure´ E, Agami R. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008, 10(2):202-210. 10.1038/ncb1681, 18193036.
21. Slaby O, Svoboda M, Michalek J, Vyzula R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer 2009, 8:102. 10.1186/1476-4598-8-102, 2780389, 19912656.
22. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R, Vyzula R. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007, 72(5-6):397-402.
23. Molina-Pinelo S, Suarez R, Pastor MD, Nogal A, Marquez-Martin E, Martin-Juan J, Carnero A, Paz-Ares L. Association between the miRNA signatures in plasma and bronchoalveolar fluid in respiratory pathologies. Dis Markers 2012, 32(4):221-230. 10.1155/2012/873749, 3826892, 22430188.
24. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk-database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform 2011, 44(5):839-847. 10.1016/j.jbi.2011.05.002, 21605702.
25. Datta J, Smith A, Lang JC, Islam M, Dutt D, Teknos TN, Pan Q. microRNA-107 functions as a candidate tumor-suppressor gene in head and neck squamous cell carcinoma by downregulation of protein kinase Cvarepsilon. Oncogene 2011, 31(36):4045-4053. 3307861, 22158047.
26. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006, 103(7):2257-2261. 10.1073/pnas.0510565103, 1413718, 16461460.
27. Van der Auwera I, Limame R, van Dam P, Vermeulen PB, Dirix LY, Van Laere SJ. Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype. Br J Cancer 2010, 103(4):532-541. 10.1038/sj.bjc.6605787, 2939785, 20664596.
28. Pan Q, Bao LW, Teknos TN, Merajver SD. Targeted disruption of protein kinase C epsilon reduces cell invasion and motility through inactivation of RhoA and RhoC GTPases in head and neck squamous cell carcinoma. Cancer Res 2006, 66(19):9379-9384. 10.1158/0008-5472.CAN-06-2646, 17018591.
29. Yamakuchi M, Lotterman CD, Bao C, Hruban RH, Karim B, Mendell JT, Huso D, Lowenstein CJ. P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci U S A 2010, 107(14):6334-6339. 10.1073/pnas.0911082107, 2851979, 20308559.
30. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshert E. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998, 394(6692):485-490. 10.1038/28867, 9697772.
31. Yu JL, Rak JW, Carmeliet P, Nagy A, Kerbel RS, Coomber BL. Heterogeneous vascular dependence of tumor cell populations. Am J Pathol 2001, 158(4):1325-1334. 10.1016/S0002-9440(10)64083-7, 1891903, 11290550.
32. Li F, Liu B, Gao Y, Liu Y, Xu Y, Tong W, Zhang A. Upregulation of MicroRNA-107 induces proliferation in human gastric cancer cells by targeting the transcription factor FOXO1. FEBS Lett 2014, 588(4):538-544. 10.1016/j.febslet.2013.12.009, 24374340.
33. Chen RH, Chen HY, Lin YM, Chung HC, Lang YD, Lin CJ, Huang J, Wang WC, Lin FM, Chen Z, Huang HD, Shyy JY, Liang JT, Chen RH. miR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4. Cancer Res 2012, 72(14):3631-3641. 10.1158/0008-5472.CAN-12-0667, 22593189.
34. Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, Kaiser B, Wick MJ, Alvarez C, Cavazos A, Mangold GL, Patnaik A. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 2012, 18(8):2316-2325. 10.1158/1078-0432.CCR-11-2381, 22261800.
35. Leong S, Messersmith WA, Tan AC, Eckhardt SG. Novel agents in the treatment of metastatic colorectal cancer. Cancer J 2010, 16(3):273-282. 10.1097/PPO.0b013e3181e076c5, 20526106.
36. Carnero A. Novel inhibitors of the PI3K family. Expert Opin Investig Drugs 2009, 18(9):1265-1277. 10.1517/13543780903066798, 19589091.
37. Carnero A. The PKB/AKT pathway in cancer. Curr Pharm Des 2010, 16(1):34-44. 10.2174/138161210789941865, 20214616.
38. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2(7):489-501. 10.1038/nrc839, 12094235.
39. Paz-Ares L, Blanco-Aparicio C, Garcia-Carbonero R, Carnero A. Inhibiting PI3K as a therapeutic strategy against cancer. Clin Transl Oncol 2009, 11(9):572-579. 10.1007/s12094-009-0407-x, 19775996.